fda powerpoint presentation: torsades de pointes and qt prolongation
DESCRIPTION
FDA Powerpoint Presentation: Torsades de Pointes and QT ProlongationTRANSCRIPT
![Page 1: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/1.jpg)
Drug-Induced QT Interval Prolongation and
Torsades de Pointes
![Page 2: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/2.jpg)
![Page 3: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/3.jpg)
Drug-Induced Torsades de Pointes Low frequency event Potentially life threatening Not highly predictable despite
known risk factors
![Page 4: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/4.jpg)
QT Prolongation & Torsades de Pointes
Cardiac electrophysiology Clinical pharmacology Genetics Regulatory medicine Clinical Practice
![Page 5: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/5.jpg)
QT Prolongation & Torsades de Pointes
Mechanisms of QT prolongation and TdP
Drug effects on the QT interval
Specific drugs associated with TdP
Risk factors for drug-induced TdP
Clinical and regulatory implications
![Page 6: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/6.jpg)
Drugs Which Prolong the QTc
http://www.dml.georgetown.edu/depts/pharmacology/torsades.htmlhttp://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/publicat/adrv8n1_e.html
Anticonvulsants Fosphenytoin; FelbamateAntihistamines Azelastine; ClemastineAnti-Infectives Amantadine; Clarithromycin; Chloroquine; Foscarnet;
Erythromycin; Halofantrine; Mefloquine; Moxifloxacin;Pentamidine; Sparfloxacin; Quinine; Trimethoprim-Sulfamethoxazole, Ketoconazole
Antineoplastics TamoxifenCardiovascular: Antiarrhythmics Amiodarone; Bretylium; Disopyramide; Flecainide;
Ibutilide; Procainamide; Quinidine; Sotalol; Dofetilide Calcium Channel Blockers Bepridil; Israpidine; Nicardipine Diuretics Indapamide; Moexipril/HCTZHormones Octreotide; VasopressinImmunosuppressives TacrolimusMigraine: Serotonin Receptor Agonists Zolmitriptan; Naratriptan; SumatriptanMuscle Relaxant TizanidineNarcotic Detoxification LevomethadylPsychotherapeutics: Antidepressants Amitriptyline; Desipramine; Fluoxetine; Imipramine; Venlafaxine Antipsychotic Chlorpromazine; Haloperidol; Pimozide; Quetiapine;
Risperidone; Thioridazine Antianxiety Doxepin Antimanic LithiumRespiratory: Sympathomimetics SalmeterolSedative/Hypnotics Chloral hydrate
![Page 7: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/7.jpg)
QT Prolongation & Torsades de Pointes
Congenital LQTS Acquired LQTS
Drugs Bradycardia Hypokalemia CHF & LVH
![Page 8: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/8.jpg)
![Page 9: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/9.jpg)
Action Potential and
Ionic Currents
![Page 10: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/10.jpg)
Ventricular Action Potential
Na+
IKr
Ca++
IKs
![Page 11: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/11.jpg)
Mechanisms Of Drug - Induced QT Prolongation and Tdp
Block of repolarizing K+ currents
Stimulation of ICa-l
Stimulation of INa
![Page 12: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/12.jpg)
HERG Channel
![Page 13: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/13.jpg)
Mechanism of Torsades de Pointes
Early afterdepolarizations
Transmural reentry
![Page 14: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/14.jpg)
Yan & Antzelevitch Circulation. 1998;98:1921-1927
![Page 15: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/15.jpg)
Yan & Antzelevitch Circulation. 1998;98:1928-1936
![Page 16: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/16.jpg)
Torsades de Pointes
EPI
M
ENDO
![Page 17: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/17.jpg)
Torsades de Pointes
![Page 18: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/18.jpg)
ECG - QT Interval
![Page 19: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/19.jpg)
Automated QT and QTc Analysis
Reliable with normal T waves at physiologic heart rates
Unreliable: High heart rates Abnormal T waves Prominent U waves
T-U wave complex morphology
![Page 20: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/20.jpg)
![Page 21: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/21.jpg)
Rate-Corrected QT Interval (QTc)
QT Interval corrected for heart rate = QTc (Bazett)
QTc =
General Population Average QTc = 380-400 msec Bazett correction has major limitations
HR 66 bpm
HR 83 bpm
QT
RR
![Page 22: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/22.jpg)
QT Correction Formulae
Original CohortFormula Mathematical
Expression for QTc NMean Age
(Range) (years)
Log-Linear
Bazett QT / (RR) 0.5 39 26 (<14-53)
Fridericia QT / (RR) 0.33 50 26 (2-81)
Baseline correction QT / (RR)0.37 NA NA
Linear
Framingham QT + 0.154 (1 – RR) 5,018 44 (28-62)
Hodges QT + 1.75 (HR – 60) 607 (20’s-80’s)
![Page 23: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/23.jpg)
Normal QTc Interval - Criteria
QTc (msec) Male Female
Normal <430 <450
Borderline 431-450 451-470
Prolonged >450 >470
![Page 24: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/24.jpg)
QT Intervals in Drug Induced TdP
89.580.2
89.5
75.5
0
25
50
75
100
Antiarrhythmic Drugs Non-Antiarrhythmic Drugs(N= 332) (N=189)
QTc
QT
Percent of Patients with QTc or QT> 500 msec (%)
Makkar et al JAMA 1993; 270: 2590-2597.Bednar & Ruskin (personal communication)
![Page 25: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/25.jpg)
70
30
67.2
32.8
0
25
50
75
Antiarrhythmics Non-Antiarrhythmics(N=332) (N=189)
Female
Male
Drug-Induced TdP - Gender Distribution
Makkar et al JAMA 1993; 270: 2590-2597.Bednar & Ruskin (personal communication)
![Page 26: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/26.jpg)
TdP - High Risk Drugs (> 1%)
Quinidine Disopyramide
Sotalol
Ibutilide
Dofetilide
Therapeutic Effect Is Linked to IKr Block
![Page 27: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/27.jpg)
TdP - Low Risk Drugs (< 0.1%)
Antihistamines Antibiotics Antiviral agents Psychotropics Many others
Therapeutic Effect Is Independent of IKr Block
![Page 28: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/28.jpg)
Drug-Induced Torsades de Pointes Primary: Drug effect (IKr block) Secondary: Effect Amplifiers
Bradycardia Hypokalemia Heart disease (LVH or CHF) Atrial fibrillation Female gender Undetected HERG mutation High doses Metabolic inhibitors (PK) Concomitant IKr blockers (PD)
![Page 29: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/29.jpg)
Effect of EC K+ on Drug Induced IKr Block
Circulation 1996 Feb 1;93(3):407-11Yang T, Roden DM
![Page 30: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/30.jpg)
Hepatic drugmetabolism
Roden, D. Cardiac Electrophysiology (Zipes & Jalife) Ch XIV WB Saunders 2000
![Page 31: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/31.jpg)
CYP450 3A4 Inhibitors
Amiodarone Cimetidine Fluoxetine Grapefruit juice Protease inhibitors Ketoconazole; itraconazole Macrolide antibiotics (not Azithromycin) Nefazadone
![Page 32: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/32.jpg)
Drug Induced Torsades de Pointes
Drug EP Effects Metabolic Liability
Terfenadine IKr blocker 3A4 substrate
Cisapride IKr blocker 3A4 substrate
Mibefradil IKr blocker 3A4 inhibitor
Erythromycin IKr blocker 3A4 inhibitor
Astemizole IKr blocker 3A4 substrate
Dofetilide IKr blocker Renal excretion
Sotalol IKr blocker Renal excretion
![Page 33: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/33.jpg)
QTc Changes with Terfenadine Effect of CYP3A4 Inhibition with Ketoconazole
0
10
20
30
40
50
60
70
80
90
TerfenadineTerfen & Keto
ChangeIn QTc(msec)
![Page 34: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/34.jpg)
Terfenadine (Seldane) 60 mg BID
* Pratt CM, et al. Am Heart J 1996; 131:472-480** Pratt CM, et al. Am J Cardiol 1994; 73: 346-352 *** Hanrahan JP, et al. Ann Epidem 1995; 5:201-209
**** Honig PK, et al. JAMA 1993; 269:1513-1518
> 100 million prescriptions
QTc Change (msec) Safety
Absence ofMetabolic Inhibitor
6-8 msec* average across dosing interval
18 msec one hour post dose
No evidence of increasedmortality in prescription-based studies N~180,000 (COMPASS)** N~20,000 (HCHP)***
Presence ofMetabolic Inhibitor
82 msec (non-peak)****(more than twenty-foldincrease in concentration)
Increased risk of suddendeath led to withdrawal
![Page 35: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/35.jpg)
Cisapride (Propulsid)
Gastric prokinetic (GERD) IKr blocker (modest QT effect) CYP 3A4 substrate Clarithromycin - 3X increase in conc Ketoconazole - 8X increase in conc 30 million Rx’s since 1993; no arrhythmia signal
in large database review 1993-1999: 270 cases of serious arrhythmias reported to
FDA (70 deaths) One AE per 111,000 and one fatality per 428,000
prescriptions (undetectable in controlled trials)
![Page 36: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/36.jpg)
TdP: Multiple-Hit Hypothesis
Drug exposure (IKr blocker)
Second risk factor Bradycardia Hypokalemia Female gender Metabolic inhibitor Other QT prolonging drugs Underlying heart disease (CHF, LVH, AF) Genetic polymorphism (IKr or IKs)
![Page 37: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/37.jpg)
Drugs Withdrawn for TdP
Drug Class Date Withdrawn
Terfenadine Antihistamine Feb 1998
Sertindole Antipsychotic Dec 1998
Astemizole Antihistamine Jun 1999
Grepafloxacin Antibiotic Nov 1999
Cisapride GI Prokinetic July 2000
![Page 38: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/38.jpg)
GAO01-286R1/19/01
![Page 39: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/39.jpg)
Drug Induced QT ProlongationPreclinical Screeing
In vitro ion channels effects IKr - cloned HERG (HEK or AT-1 cells) Ica & INa
In vitro APD effects Isolated myocytes (dog,rabbit,g. pig) Purkinje fibers (dog,rabbit) Papillary muscle (guinea pig)
Wide range of concentrations (100-1000X) Wide range of rates Metabolites
![Page 40: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/40.jpg)
Drug Induced QT ProlongationPreclinical Screeing
Other In vitro models LV wedge (perfused canine) Perfused rabbit heart ( HR & K+)
In vivo models Conscious rabbit Anesthetized methoxamine sensitized rabbit Canine chronic AV block
![Page 41: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/41.jpg)
Evaluation of New Drugs - Risk Assessment
Preclinical profile QT effects in humans
Mean & mean max changes c/w PBO Categorical analysis Outliers Special populations
Torsades de Pointes VT, VF & cardaic arrest Syncope Sudden death
![Page 42: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/42.jpg)
Drug-Induced TdP
Drug - drug interactions Pharmacokinetic Pharmacodynamic
Drug - gene interactions Genetic polymorphisms Acquired repolarization reserve (CHF)
![Page 43: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/43.jpg)
Drugs Which Cause TdP
Almost all are IKr blockers
Preclinical profile cannot exclude risk
Many are CYP 450 3A4 substrates
Numerous cofactors enhance risk
TdP rarely detected in drug development
![Page 44: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/44.jpg)
Drug Induced QT Prolongation
Preclinical findings QT effects in humans Adverse event profile Therapeutic target(s) Relative efficacy Unique advantages Alternative options Risk:benefit assessment
![Page 45: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/45.jpg)
![Page 46: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/46.jpg)
Post-CABG Day 4 (on Fluconazole)
QT=380 QTc=460QT=380 QTc=460
![Page 47: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/47.jpg)
QTc 516 ms on fluconazoleQTc normal preop
Post-CABG Day 3
![Page 48: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/48.jpg)
![Page 49: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/49.jpg)
![Page 50: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/50.jpg)
Amiodarone
QT 621QTc 747HR 87
Long-short-> TdP
![Page 51: FDA Powerpoint Presentation: Torsades de Pointes and QT Prolongation](https://reader031.vdocument.in/reader031/viewer/2022031904/55cf9a1b550346d033a07d1b/html5/thumbnails/51.jpg)